ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

ISA announces successful closing of EUR 26 million funding round

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

ISA has relocated to brand new Biopartner 5 building

ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®

ISA106 – SLP therapeutic for COVID-19